Schwab Charles Investment Management Inc. Acquires New Position in Adverum Biotechnologies Inc (ADVM)

Share on StockTwits

Schwab Charles Investment Management Inc. purchased a new position in shares of Adverum Biotechnologies Inc (NASDAQ:ADVM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 113,677 shares of the biotechnology company’s stock, valued at approximately $603,000. Schwab Charles Investment Management Inc. owned approximately 0.18% of Adverum Biotechnologies as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Creative Planning grew its position in Adverum Biotechnologies by 76.8% during the second quarter. Creative Planning now owns 22,870 shares of the biotechnology company’s stock worth $121,000 after buying an additional 9,937 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Adverum Biotechnologies during the first quarter worth about $262,000. Rhumbline Advisers acquired a new position in Adverum Biotechnologies during the second quarter worth about $292,000. Barclays PLC grew its position in Adverum Biotechnologies by 178.4% during the first quarter. Barclays PLC now owns 95,883 shares of the biotechnology company’s stock worth $556,000 after buying an additional 61,438 shares during the period. Finally, Northern Trust Corp grew its position in Adverum Biotechnologies by 24.3% during the first quarter. Northern Trust Corp now owns 99,838 shares of the biotechnology company’s stock worth $579,000 after buying an additional 19,488 shares during the period. 58.39% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have weighed in on ADVM. BidaskClub lowered shares of Adverum Biotechnologies from a “buy” rating to a “hold” rating in a research report on Friday, August 3rd. SunTrust Banks began coverage on shares of Adverum Biotechnologies in a research report on Thursday, August 30th. They set a “buy” rating and a $11.00 target price on the stock. Raymond James lowered shares of Adverum Biotechnologies from an “outperform” rating to a “market perform” rating in a research report on Friday, November 2nd. ValuEngine lowered shares of Adverum Biotechnologies from a “buy” rating to a “hold” rating in a research report on Friday, September 14th. Finally, Cantor Fitzgerald set a $12.00 target price on shares of Adverum Biotechnologies and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $6.85.

Shares of ADVM stock traded up $0.02 during trading hours on Friday, hitting $3.76. The company’s stock had a trading volume of 261,560 shares, compared to its average volume of 1,131,395. The firm has a market capitalization of $231.34 million, a PE ratio of -2.91 and a beta of 3.83. Adverum Biotechnologies Inc has a twelve month low of $2.62 and a twelve month high of $8.59.

Adverum Biotechnologies (NASDAQ:ADVM) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The business had revenue of $0.83 million during the quarter, compared to analyst estimates of $0.27 million. Adverum Biotechnologies had a negative net margin of 3,957.63% and a negative return on equity of 30.61%. Sell-side analysts expect that Adverum Biotechnologies Inc will post -1.23 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Equities Focus and is owned by of Equities Focus. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.equitiesfocus.com/2018/11/10/schwab-charles-investment-management-inc-purchases-shares-of-113677-adverum-biotechnologies-inc-advm.html.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply